Information about medicinal products published on this website is provided for informational purposes only and does not constitute advertising, a public offer, an offer for sale, or instructions for use.
The use of medicinal products is permitted only upon a doctor’s prescription. Consultations are provided by clinic specialists in person or online in accordance with applicable law.
The use of medicinal products is permitted only upon a doctor’s prescription. Consultations are provided by clinic specialists in person or online in accordance with applicable law.
DAXAS (ITALY)
1 tablet contains 500 mcg of roflumilast.
Composition
Active ingredient: roflumilast
Pharmacotherapeutic group
Drugs used in obstructive airway diseases. Other systemic drugs for obstructive airway diseases.
Indications
For maintenance therapy of severe chronic obstructive pulmonary disease (COPD) (forced expiratory volume in one second [FEV1] after bronchodilator use less than 50% of predicted) associated with chronic bronchitis in adults and with a history of frequent COPD exacerbations, as an add-on to bronchodilator therapy.
Contraindications
Hypersensitivity to roflumilast or any other components of the medication.
Moderate or severe liver failure.
Dosage and administration
The recommended dose for adults is 1 tablet (500 mcg of roflumilast) once daily.
It may take several weeks of treatment to achieve a therapeutic effect.
Method of administration
For oral use.
The tablet should be swallowed with water. The medication should be taken daily at the same time. Tablets can be taken with or without food.
Children
Daxas is not used in children (under 18 years of age) for the indication of COPD.
Dosage form: 500 mcg tablets.
Package contains 30 tablets.
Active ingredient: roflumilast
Pharmacotherapeutic group
Drugs used in obstructive airway diseases. Other systemic drugs for obstructive airway diseases.
Indications
For maintenance therapy of severe chronic obstructive pulmonary disease (COPD) (forced expiratory volume in one second [FEV1] after bronchodilator use less than 50% of predicted) associated with chronic bronchitis in adults and with a history of frequent COPD exacerbations, as an add-on to bronchodilator therapy.
Contraindications
Hypersensitivity to roflumilast or any other components of the medication.
Moderate or severe liver failure.
Dosage and administration
The recommended dose for adults is 1 tablet (500 mcg of roflumilast) once daily.
It may take several weeks of treatment to achieve a therapeutic effect.
Method of administration
For oral use.
The tablet should be swallowed with water. The medication should be taken daily at the same time. Tablets can be taken with or without food.
Children
Daxas is not used in children (under 18 years of age) for the indication of COPD.
Dosage form: 500 mcg tablets.
Package contains 30 tablets.
